Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Vilanterol - GSK/Innoviva

Next Previous
Drug Profile

Vilanterol - GSK/Innoviva

Alternative Names: 642444; GSK-642444; GW 642444; GW642444H; GW642444M; GW642444X; Vilanterol trifenatate

Latest Information Update: 20 Aug 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator GlaxoSmithKline
  • Developer GlaxoSmithKline; GSK; Innoviva; Theravance
  • Class Antiasthmatics; Chlorobenzenes; Ethers; Phenols; Small molecules
  • Mechanism of Action Beta 2 adrenergic receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Asthma; Chronic obstructive pulmonary disease

Most Recent Events

  • 20 Aug 2024 Discontinued - Phase-II for Asthma (Combination therapy, In children) in Brazil (Inhalation)
  • 20 Aug 2024 Discontinued - Phase-II for Asthma (Combination therapy, In children) in Georgia (Inhalation)
  • 20 Aug 2024 Discontinued - Phase-II for Asthma (Combination therapy, In children) in Japan (Inhalation)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top